Hady Ghanem, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Jorge Cortes, Lakshmikanth Katragadda, Susan O'Brien, Naval Daver, Sherry Pierce, Tapan Kadia, Hagop Kantarjian, Elias Jabbour
BACKGROUND: The outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post clofarabine is unknown. METHODS: We reviewed 109 patients with MDS or CMML with a median age of 67 years, treated with a clofarabine-based chemotherapy as frontline (n = 38) or salvage (n = 71) therapy. A total of 58 (53%) patients received salvage therapy after clofarabine failure: 13 allogeneic stem cell transplant (ASCT), 18 high-dose cytarabine-containing regimen, 10 hypomethylating agents and 17 investigational treatments...
April 2014: Therapeutic Advances in Hematology